000142133 001__ 142133
000142133 005__ 20240229112528.0
000142133 0247_ $$2doi$$a10.1002/ijc.31634
000142133 0247_ $$2pmid$$apmid:29943826
000142133 0247_ $$2ISSN$$a0020-7136
000142133 0247_ $$2ISSN$$a1097-0215
000142133 0247_ $$2altmetric$$aaltmetric:44229378
000142133 037__ $$aDKFZ-2018-02363
000142133 041__ $$aeng
000142133 082__ $$a610
000142133 1001_ $$aSen, Abhijit$$b0
000142133 245__ $$aCoffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
000142133 260__ $$aBognor Regis$$bWiley-Liss$$c2019
000142133 3367_ $$2DRIVER$$aarticle
000142133 3367_ $$2DataCite$$aOutput Types/Journal article
000142133 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1549632916_21031
000142133 3367_ $$2BibTeX$$aARTICLE
000142133 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142133 3367_ $$00$$2EndNote$$aJournal Article
000142133 520__ $$aThe epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94-1.09) and 0.98 (95% CI, 0.90-1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79-1.21) and 0.89 (95% CI, 0.70-1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
000142133 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142133 588__ $$aDataset connected to CrossRef, PubMed,
000142133 7001_ $$aPapadimitriou, Nikos$$b1
000142133 7001_ $$aLagiou, Pagona$$b2
000142133 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b3
000142133 7001_ $$aTravis, Ruth C$$b4
000142133 7001_ $$aKey, Timothy J$$b5
000142133 7001_ $$00000-0003-3347-8249$$aMurphy, Neil$$b6
000142133 7001_ $$aGunter, Marc$$b7
000142133 7001_ $$aFreisling, Heinz$$b8
000142133 7001_ $$aTzoulaki, Ioanna$$b9
000142133 7001_ $$aMuller, David C$$b10
000142133 7001_ $$aCross, Amanda J$$b11
000142133 7001_ $$aLopez, David S$$b12
000142133 7001_ $$aBergmann, Manuela$$b13
000142133 7001_ $$aBoeing, Heiner$$b14
000142133 7001_ $$aBamia, Christina$$b15
000142133 7001_ $$aKotanidou, Anastasia$$b16
000142133 7001_ $$aKarakatsani, Anna$$b17
000142133 7001_ $$aTjønneland, Anne$$b18
000142133 7001_ $$00000-0002-9083-8960$$aKyrø, Cecilie$$b19
000142133 7001_ $$aOutzen, Malene$$b20
000142133 7001_ $$aRedondo, María-Luisa$$b21
000142133 7001_ $$aCayssials, Valerie$$b22
000142133 7001_ $$aChirlaque, Maria-Dolores$$b23
000142133 7001_ $$aBarricarte, Aurelio$$b24
000142133 7001_ $$aSánchez, Maria-Jose$$b25
000142133 7001_ $$aLarrañaga, Nerea$$b26
000142133 7001_ $$aTumino, Rosario$$b27
000142133 7001_ $$aGrioni, Sara$$b28
000142133 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b29
000142133 7001_ $$aCaini, Saverio$$b30
000142133 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b31
000142133 7001_ $$aBueno-de-Mesquita, Bas$$b32
000142133 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b33$$udkfz
000142133 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b34$$udkfz
000142133 7001_ $$aNilsson, Lena Maria$$b35
000142133 7001_ $$aLandberg, Rikard$$b36
000142133 7001_ $$aWallström, Peter$$b37
000142133 7001_ $$00000-0002-6500-6310$$aDrake, Isabel$$b38
000142133 7001_ $$aBech, Bodil Hammer$$b39
000142133 7001_ $$aOvervad, Kim$$b40
000142133 7001_ $$aAune, Dagfinn$$b41
000142133 7001_ $$aKhaw, Kay-Tee$$b42
000142133 7001_ $$aRiboli, Elio$$b43
000142133 7001_ $$aTrichopoulos, Dimitrios$$b44
000142133 7001_ $$aTrichopoulou, Antonia$$b45
000142133 7001_ $$00000-0002-8452-8472$$aTsilidis, Konstantinos K$$b46
000142133 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31634$$gVol. 144, no. 2, p. 240 - 250$$n2$$p240 - 250$$tInternational journal of cancer$$v144$$x0020-7136$$y2019
000142133 909CO $$ooai:inrepo02.dkfz.de:142133$$pVDB
000142133 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000142133 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000142133 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142133 9141_ $$y2019
000142133 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142133 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142133 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142133 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142133 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000142133 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142133 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142133 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142133 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142133 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142133 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142133 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000142133 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000142133 980__ $$ajournal
000142133 980__ $$aVDB
000142133 980__ $$aI:(DE-He78)C020-20160331
000142133 980__ $$aUNRESTRICTED